World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
41874
World Ranking
16883
National Ranking
8466

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Ingo K. Mellinghoff is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily spans the field of medicine, with specific contributions to genetics, pulmonary and respiratory medicine, cancer research, oncology, and radiology, nuclear medicine, and imaging.

Their work has advanced multiple areas of study including glioma diagnosis and treatment, cancer genomics and diagnostics, radiomics and machine learning in medical imaging, brain metastases and treatment, cancer, hypoxia, and metabolism, neuroblastoma research and treatments, and cancer immunotherapy and biomarkers.

Frequent collaborators include Patrick Y. Wen, Timothy F. Cloughesy, Benjamin M. Ellingson, Islam Hassan, and Martin J. van den Bent.

Notable recent publications by Ingo K. Mellinghoff include:

  • Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma, 2023, New England Journal of Medicine
  • Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma, 2020, Journal of Clinical Oncology

Other influential papers linked to their research network include:

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions, 2020, Neuro-Oncology
  • Glioblastoma and Other Primary Brain Malignancies in Adults, 2023, JAMA
  • Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter, 2022, Neuro-Oncology

The primary venues for publishing their research contributions include Neuro-Oncology, Journal of Clinical Oncology, Cancer Research, Clinical Cancer Research, and Neuro-Oncology Advances.

Ingo K. Mellinghoff has been recognized as a member of the Association of American Physicians.

Best Publications

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • IDH mutation impairs histone demethylation and results in a block to cell differentiation

    Chao Lu;Patrick S. Ward;Patrick S. Ward;Gurpreet S. Kapoor;Dan Rohle;Dan Rohle

  • IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

    Sevin Turcan;Daniel Rohle;Daniel Rohle;Anuj Goenka;Logan A. Walsh

  • Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

    Ingo K. Mellinghoff;Maria Y. Wang;Igor Vivanco;Daphne A. Haas-Kogan

  • Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma

    Rameen Beroukhim;Gad Getz;Leia Nghiemphu;Jordi Barretina

  • Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR

    Mehran S. Neshat;Ingo K. Mellinghoff;Chris Tran;Bangyan Stiles

  • An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells

    Dan Rohle;Janeta Popovici-Muller;Nicolaos Palaskas;Sevin Turcan

  • A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle

    Moritz F Kircher;Adam de la Zerda;Jesse V Jokerst;Cristina L Zavaleta

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.

    Timothy F. Cloughesy;Aaron Y. Mochizuki;Joey R. Orpilla;Willy Hugo

  • Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

    George V Thomas;Chris Tran;Ingo K Mellinghoff;Derek S Welsbie

  • Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

    Patrick Y. Wen;Michael Weller;Eudocia Quant Lee;Brian M. Alexander

  • Challenges to curing primary brain tumours

    Kenneth Aldape;Kevin M Brindle;Louis Chesler;Rajesh Chopra

  • Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

    Tim F Cloughesy;Koji Yoshimoto;Phioanh Leia Nghiemphu;Kevin Brown

  • Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid

    Alexandra M. Miller;Ronak H. Shah;Elena I. Pentsova;Maryam Pourmaleki

  • Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer

    Lucia Regales;Yixuan Gong;Ronglai Shen;Elisa de Stanchina

  • An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR/AKT/SREBP-1/LDLR–Dependent Pathway

    Deliang Guo;Felicia Reinitz;Mary Youssef;Cynthia Hong

  • Somatic mutations of the Parkinson's disease–associated gene PARK2 in glioblastoma and other human malignancies

    Selvaraju Veeriah;Barry S Taylor;Shasha Meng;Fang Fang

  • HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

    Ingo K. Mellinghoff;Igor Vivanco;Andrew Kwon;Chris Tran

  • A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle

    Adam de la Zerda;Moritz F. Kircher;Moritz F. Kircher;Jesse V. Jokerst;Cristina L. Zavaleta

Frequent Co-Authors

Timothy F. Cloughesy
Timothy F. Cloughesy University of California, Los Angeles
Patrick Y. Wen
Patrick Y. Wen Harvard University
Lisa M. DeAngelis
Lisa M. DeAngelis Memorial Sloan Kettering Cancer Center
Rameen Beroukhim
Rameen Beroukhim Harvard University
Paul S. Mischel
Paul S. Mischel Stanford University
Cameron Brennan
Cameron Brennan Memorial Sloan Kettering Cancer Center
Charles L. Sawyers
Charles L. Sawyers Memorial Sloan Kettering Cancer Center
Michael D. Prados
Michael D. Prados University of California, San Francisco
Linda M. Liau
Linda M. Liau University of California, Los Angeles
Susan M. Chang
Susan M. Chang University of California, San Francisco

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in a medical career but seeking alternatives to the traditional MD route? Today, there are many flexible online programs that open the door to rewarding roles within healthcare. For those wanting to shape healthcare leadership, exploring the masters in healthcare administration cost can help you understand both the financial and professional benefits of this in-demand path.

Nursing professionals looking to take their expertise to the highest level can consider the best online dnp programs, which are designed for advanced clinical leadership. Meanwhile, aspiring pharmacists have increasingly viable remote learning options. Learn about pharmacy school online—ideal for those balancing studies with other commitments.

Finally, for individuals interested in health technology and data, an online health information management degree can position you in a growing area that blends healthcare and IT.

These online degrees can accelerate your journey into healthcare, offering flexibility, affordability, and career growth.

Best Scientists Citing Ingo K. Mellinghoff

Trending Scientists

Recently Published Articles